F70

VERIFICATION OF CELL PRODUCT

Page 1 of 2

⊖HPC, Marrow	OHPC, Apheresis		○MNC, Apheresis			
PATIENT DATA						
Patient first name:		Patient last name:				
Patient registry:		1				
Transplant centre:						
Patient ID:		Patient ID:				
(assigned by patient registry) Date of birth: (YYYY-MM-DD)	Gender:	(assigned by donor registry) Weight: (kg)	Blood group/RhD:			
	Gender.	vvergrit. (kg)	Blood gloup/RIID.			
DONOR DATA						
Donor registry:			ION:			
Donor ID:						
GRID:						
Date of birth: (YYYY-MM-DD)	Gender:	Weight: (kg)	Blood group/RhD:			
SECTION A: to be completed by the don	or centre					
Commonto						
Comments:						
Person completing form:	Date: (YYYY-MM-DD)		Donor centre signature:			
			5			
	I					
SECTION B: to be completed by the colle	ection/apheresis co	enter				
Institution:						
Address:						
		Collection date(s): (YYYY-MM-DD)				
ZIP code:		Start date G-CSF: (YYYY-MM-DD)				
City:		Anticoagulants: Heparin ACD EDTA				
Country:		Other: Volume/ratio: Peripheral blood to be collected at the time of the collection:				
			ml heparin ml ACD			
Phone:		ml EDTA ml no anti-coagulant				
Fax:			v			
E-mail: ml product tube, type: Based on the experience at this centre, we feel that the requested amount of cells is:						
 Feasible Note that this is not a guarantee that the requested number of cells will be supplied. The number of Not feasible collected cells may be larger or smaller. 						
Comments:						
Porson comploting form:	Data: MARIAR		Collection/apheresis centre signature:			
Person completing form:	Date: (YYYY-MM-DD)		conection/aprieresis centre signature.			
2						

©umda

F70

VERIFICATION OF CELL PRODUCT

Page 2 of 2

⊖HPC, Marrow	OHPC, Apheresis	○MNC, Apheresis	
PATIENT DATA			
Patient first name:	Patient	Patient last name:	
Patient registry:	· · ·		
Transplant centre:			
Patient ID: (assigned by patient registry)	Patient (assigned l	ID: by donor registry)	
	÷		

DONOR DATA

Donor registry:	ION:
Donor ID:	
GRID:	

DISCLAIMER:

- The cell products collected from this donor are intended solely for the purpose of immediate therapeutic treatment for the above mentioned patient. Any planned cryopreservation of the cell products prior to initial infusion to the patient may only occur with the advance written approval from the donor centre.
- Excess cells may be stored for future therapeutic treatment for this patient. No other uses of these cells are permissible. Cells not used for the therapeutic treatment of the above mentioned patient must be disposed of properly and details must be provided to the donor centre.
- The donor centre must be provided detailed information concerning the use and/or disposal of all portions of this cell product. By accepting these cells, the transplant physician also accepts these terms and conditions. Deviations from these terms are not permitted without prior written approval from the donor centre.
- Any serious product events and/or adverse reactions must be reported both to the donor's registry and transplant centre. Corresponding SEAR/SPEAR reports must be completed by the registry providing the product, submitted to the WMDA office and details must provided to the donor centre.

SECTION C: transplant centre acceptance of terms provided by donor & collection/apheresis centres					
Person completing form:	Date: (YYYY-MM-DD)	Transplant centre signature:			

